Datopotamab Deruxtecan Showed Promising Responses as Monotherapy and in Combination with Durvalumab in Patients with Metastatic Triple Negative Breast Cancer in Two Early Trials
Daiichi Sankyo and AstraZeneca’s TROP2 directed ADC showed an encouraging objective response rate of 32%…